Guidelines

Von Willebrand disease guidelines address women’s bleeding concerns


 

FROM BLOOD ADVANCES

Major surgery

This section includes a recommendation for targeting both factor VIII and VWF activity levels to a minimum of 50 IU/mL for at least 3 days after surgery, and a suggestion against using factor VIII target levels alone.

Minor surgery/invasive procedures

The panelists suggest increasing VWF activity levels to a minimum of 0.50 IU/mL with desmopressin or factor concentrate with the addition of tranexamic acid over raising VWF levels to at least 0.50 IU/mL with desmopressin or factor concentrate alone.

In addition, the panelists suggest “giving tranexamic acid alone over increasing VWF activity levels to a minimum threshold of 0.50 IU/mL with any intervention in patients with type 1 VWD with baseline VWF activity levels of 0.30 IU/mL and a mild bleeding phenotype undergoing minor mucosal procedures.”

Heavy menstrual bleeding

In women with heavy menstrual bleeding who do not plan to conceive, the panel suggests either combined hormonal therapy or levonorgestrel-releasing intrauterine system, or tranexamic acid over desmopressin.

In women who wish to conceive, the panel suggests using tranexamic acid over desmopressin.

Neuraxial anesthesia during labor

For women in labor for whom neuraxial anesthesia is considered, the guidelines suggest targeting a VWF activity level from 0.50 to 1.50 IU/mL over targeting a level above 1.50 IU/mL.

Postpartum management

“The guideline panel suggests the use of tranexamic acid over not using it in women with type 1 VWD or low VWF levels (and this may also apply to types 2 and 3 VWD) during the postpartum period,” the guidelines say.

An accompanying good practice statement says that tranexamic acid can be provided orally or intravenously. The oral dose is 25 mg/kg three times daily for 10-14 days, or longer if blood loss remains heavy.

Dr. Flood said that the guidelines were developed under the assumption that they would apply to care of patients in regions with a high or moderately high degree of clinical resources.

“We recognize that this eliminates a great deal of the globe, and our hope is that ASH and the other sponsoring organizations are going to let us revise this and do a version for lower-resourced settings,” she said.

Pages

Recommended Reading

Subcutaneous hep A vaccination as effective as intramuscular for bleeding disorder patients
MDedge Internal Medicine
Large cohort study: Bevacizumab safe, effective for severe HHT bleeds
MDedge Internal Medicine
Low VWF levels or blood group O not linked to intracerebral hemorrhage risk
MDedge Internal Medicine
INR fails to predict bleeding in patients with cirrhosis
MDedge Internal Medicine
Mouth splints decrease risk of post–dental extraction bleeding in hemophilia
MDedge Internal Medicine
Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction
MDedge Internal Medicine
Cost is the main hurdle to broad use of caplacizumab for TTP
MDedge Internal Medicine
Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A
MDedge Internal Medicine
A 4-point thrombocytopenia score was found able to rule out suspected HIT
MDedge Internal Medicine
In COVID-19 patients, risk of bleeding rivals risk of thromboembolism
MDedge Internal Medicine